Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Sanofi (NASDAQ:SNY) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $62.6667.

SNY has been the subject of several research reports. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th.

Sanofi Trading Up 0.0%

NASDAQ SNY opened at $48.34 on Friday. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16. The stock has a market cap of $118.69 billion, a PE ratio of 11.32, a PEG ratio of 1.31 and a beta of 0.44. The company’s 50-day moving average price is $49.69 and its 200-day moving average price is $48.92. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, topping the consensus estimate of $1.60 by $1.31. The firm had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company’s revenue was down 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.25 EPS. Equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi News Roundup

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi agreed to acquire Dynavax Technologies for about $2.2 billion in cash, offering $15.50/share (roughly a 39% premium) — a deal that immediately adds a marketed adult hepatitis B vaccine (HEPLISAV‑B) and a phase 1/2 shingles candidate, strengthening Sanofi’s adult immunization franchise and providing near‑term revenue and pipeline diversification. Sanofi to acquire US biotech Dynavax for $2.2 billion
• Positive Sentiment: The company issued a formal press release highlighting HEPLISAV‑B and the shingles candidate as strategic fits for Sanofi’s adult vaccines strategy, supporting management’s message that the deal fills portfolio gaps after recent clinical setbacks. Press Release: Sanofi to acquire Dynavax
• Neutral Sentiment: Reports show an anomalous short‑interest entry (0 shares; increase flagged as NaN) with a 0.0 days‑to‑cover metric — appears to be a data artefact and is unlikely to meaningfully affect supply/demand today. (Not a substantive change in market positioning.)
• Negative Sentiment: The FDA issued a Complete Response Letter for tolebrutinib in non‑relapsing secondary progressive MS (nrSPMS) after multiple review extensions — a material regulatory setback that delays potential approval and removes an anticipated growth driver. FDA Issues CRL to SNY’s Regulatory Filing for Multiple Sclerosis Drug

Institutional Trading of Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the business. Capital Analysts LLC raised its position in Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after purchasing an additional 204 shares during the period. Advisory Services Network LLC lifted its stake in Sanofi by 1.4% in the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after acquiring an additional 210 shares during the last quarter. Thomasville National Bank lifted its position in shares of Sanofi by 0.3% during the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after purchasing an additional 211 shares during the last quarter. Waterfront Wealth Inc. boosted its position in shares of Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after acquiring an additional 214 shares in the last quarter. Finally, HighPoint Advisor Group LLC boosted its holdings in Sanofi by 2.3% in the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after purchasing an additional 226 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.